Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Alnylam launches phase I trial of transthyretin-mediated amyloidosis therapy

March 20, 2012

Phase I trial assesses interaction between diabetes therapies

March 20, 2012

Novel hedgehog pathway activators divulged by Fate Therapeutics

March 19, 2012

Novel somatostatin sst5 receptor antagonists developed

March 19, 2012

Medivir to file application for phase I trials of bone disorder candidate

March 19, 2012

Shionogi & Co. divulges novel potential obesity drugs

March 16, 2012

Studies demonstrate various therapeutic applications for SEH inhibition

March 16, 2012

First oral contraceptive for heavy menstrual bleeding approved in U.S.

March 15, 2012

Shire withdraws BLA for Fabry's disease therapy

March 15, 2012

Amgen reports new myostatin-binding antibodies

March 15, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...